MaaT Pharma SA (MAAT.PA)
| Previous close | 7.36 |
| Open | 7.38 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 7.30 - 7.42 |
| 52-week range | 5.80 - 9.90 |
| Volume | |
| Avg. volume | 1,163 |
| Market cap | 102.233M |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.70 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.00 |
Business WireMaaT Pharma Publishes its Half Year 2024 Results and Provides a Business Update
LYON, France, September 19, 2024--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced its half year financial results for the six-month period ended June 30, 2024, and provided a business overview.
Business WireMaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
LYON, France, September 09, 2024--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, today published the number of shares comprising the share capital and the total number of voting rights (Article L. 233-8 of the French Commercial Code (Code de commerce) and Article 223-16 of the General Regulations of French Autori
Business WireMaaT Pharma To Present and Participate in Investor and Medical Conferences in September
LYON, France, September 04, 2024--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival of patients with cancer, announced that it will present two posters at the Society of Hematologic Oncology Annual Meeting taking place September 4-7, 2024, in Houston, Texas, USA. In addition, MaaT Pharma announced that Company management will participate in
